149 related articles for article (PubMed ID: 19652992)
1. Rituximab sensitizes a Burkitt lymphoma cell line to cell killing by X-irradiation.
Fengling M; Fenju L; Wanxin W; Lijia Z; Jiandong T; Zu W; Xin Y; Qingxiang G
Radiat Environ Biophys; 2009 Nov; 48(4):371-8. PubMed ID: 19652992
[TBL] [Abstract][Full Text] [Related]
2. Influx of extracellular calcium participates in rituximab-enhanced ionizing radiation-induced apoptosis in Raji cells.
Fengling M; Qingxiang G; Lijia Z; Wei Z
Toxicol Lett; 2012 Mar; 209(3):221-6. PubMed ID: 22245670
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells.
Skvortsova I; Popper BA; Skvortsov S; Saurer M; Auer T; Moser R; Kamleitner H; Zwierzina H; Lukas P
J Radiat Res; 2005 Jun; 46(2):241-8. PubMed ID: 15988143
[TBL] [Abstract][Full Text] [Related]
4. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms.
Skvortsova I; Skvortsov S; Popper BA; Haidenberger A; Saurer M; Gunkel AR; Zwierzina H; Lukas P
J Radiat Res; 2006 Jun; 47(2):183-96. PubMed ID: 16819145
[TBL] [Abstract][Full Text] [Related]
5. Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab.
Barboza NM; Medina DJ; Budak-Alpdogan T; Aracil M; Jimeno JM; Bertino JR; Banerjee D
Cancer Biol Ther; 2012 Jan; 13(2):114-22. PubMed ID: 22336911
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate.
Sieber S; Gdynia G; Roth W; Bonavida B; Efferth T
Int J Oncol; 2009 Jul; 35(1):149-58. PubMed ID: 19513562
[TBL] [Abstract][Full Text] [Related]
7. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
Vega MI; Huerta-Yepez S; Jazirehi AR; Garban H; Bonavida B
Oncogene; 2005 Dec; 24(55):8114-27. PubMed ID: 16103877
[TBL] [Abstract][Full Text] [Related]
8. Radiosensitizing effects of gefitinib at different administration times in vitro.
Zhuang HQ; Sun J; Yuan ZY; Wang J; Zhao LJ; Wang P; Ren XB; Wang CL
Cancer Sci; 2009 Aug; 100(8):1520-5. PubMed ID: 19432883
[TBL] [Abstract][Full Text] [Related]
9. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.
Gu JJ; Hernandez-Ilizaliturri FJ; Mavis C; Czuczman NM; Deeb G; Gibbs J; Skitzki JJ; Patil R; Czuczman MS
Anticancer Drugs; 2013 Nov; 24(10):1030-8. PubMed ID: 23995855
[TBL] [Abstract][Full Text] [Related]
10. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
11. Surface levels of CD20 determine anti-CD20 antibodies mediated cell death in vitro.
Singh V; Gupta D; Arora R; Tripathi RP; Almasan A; Macklis RM
PLoS One; 2014; 9(11):e111113. PubMed ID: 25364827
[TBL] [Abstract][Full Text] [Related]
12. Sulfonyl chromen-4-ones (CHW09) shows an additive effect to inhibit cell growth of X-ray irradiated oral cancer cells, involving apoptosis and ROS generation.
Tang JY; Shu CW; Wang CL; Wang SC; Chang MY; Lin LC; Chang HW
Int J Radiat Biol; 2019 Sep; 95(9):1226-1235. PubMed ID: 31141432
[No Abstract] [Full Text] [Related]
13. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species.
Bellosillo B; Villamor N; López-Guillermo A; Marcé S; Esteve J; Campo E; Colomer D; Montserrat E
Blood; 2001 Nov; 98(9):2771-7. PubMed ID: 11675350
[TBL] [Abstract][Full Text] [Related]
14. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis.
Stel AJ; Ten Cate B; Jacobs S; Kok JW; Spierings DC; Dondorff M; Helfrich W; Kluin-Nelemans HC; de Leij LF; Withoff S; Kroesen BJ
J Immunol; 2007 Feb; 178(4):2287-95. PubMed ID: 17277134
[TBL] [Abstract][Full Text] [Related]
15. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
[TBL] [Abstract][Full Text] [Related]
16. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
17. Curcumin improves the antitumor effect of X-ray irradiation by blocking the NF-κB pathway: an in-vitro study of lymphoma.
Qiao Q; Jiang Y; Li G
Anticancer Drugs; 2012 Jul; 23(6):597-605. PubMed ID: 22273827
[TBL] [Abstract][Full Text] [Related]
18. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis.
Jazirehi AR; Gan XH; De Vos S; Emmanouilides C; Bonavida B
Mol Cancer Ther; 2003 Nov; 2(11):1183-93. PubMed ID: 14617792
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide and radiation enhance apoptotic effects in HL-60 cells through increased ROS generation and regulation of JNK and p38 MAPK signaling pathways.
Ho SY; Wu WJ; Chiu HW; Chen YA; Ho YS; Guo HR; Wang YJ
Chem Biol Interact; 2011 Sep; 193(2):162-71. PubMed ID: 21741957
[TBL] [Abstract][Full Text] [Related]
20. UVA Radiation Enhances Lomefloxacin-Mediated Cytotoxic, Growth-Inhibitory and Pro-Apoptotic Effect in Human Melanoma Cells through Excessive Reactive Oxygen Species Generation.
Beberok A; Rzepka Z; Rok J; Banach K; Wrześniok D
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
